Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/Ib Trial of Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC

NCT03177291 is registered in ClinicalTrials.gov with H. Lee Moffitt Cancer Center and Research Institute as lead sponsor.

NCT NCT03177291
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03177291 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/Ib Trial of Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Phase
Phase 1
Overall status
Completed
Start date
September 26, 2017
Completion date
December 4, 2024
Enrollment
48 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, lung cancer, metastatic lung cancer, non small cell lung cancer, non-squamous non-small cell neoplasm of lung, squamous cell lung cancer